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• Avenue of the Americas, New York, NY 10010 punished responding test. In contrast, microinjection of NPY into the central nucleus of the amygdala did not increase food intake in free-feeding animals, did not affect unpunished lever pressing for food, but did reproduce the anticonflictlanxiolytic-like effect with high potency. The selective NPY-YI agonist, p[Leu 31 ,Pro 3 4]NPY was approximately equipotent with native NPY in the conflict paradigm, and markedly more potent than the Y2 agonist, NPY 13 -3 6. Intrastriatal injections had no effect on conflict behavior. Thus, activation of YI receptors in the central nucleus of the amygdala produces effects similar to established anxiolytics without affecting food intake, suggesting that YI-receptors in the amygdala may be a substrate for anxiolytic actions of NPY. [Neuropsychopharmacology 8:357-363, 1993] anxiolytic-like action are prominent (for review see Hei lig and Widerlov 1990) . The latter action of the peptide is particularly interesting in conjunction with reports that NPY may be involved in the pathophysiology of depressive and/or anxiety symptoms in humans (Wider lov et al. 1988; Heilig and Widerlov 1990; Widdowson et al. 1992) .
The anxiolytic-like action of NPY has been observed in diff erent animal models of anxiety, but has only been reported after intracerebroventricular (ICV) adminis tration of the peptide (Heilig et al. 1989) . Therefore, the anatomic structures mediating this action of NPY re main unknown. Furthermore, ICV administration of NPY is sufftcient to increase food intake (Clark et al. 1984) . Therefore, an increased appetitive drive could constitute a confounding factor when apparent anxio lytic-like effects of NPY are observed after ICV adminis-0893-133X/93/$6.00 tration, in particular in tests that rely on measures of consummatory behaviors.
It has been established that hypothalamic structures mediate the effects of NPY on food intake (Stanley and Leibovitz 1985; Levine and Morley 1984) . Conversely, the amygdaloid complex and in particular the central nucleus of the amygdala are known to be important for emotionality, and the central nucleus receives a dense NPY -ergic innervation (Chronwall et al. 1985; Zardetto Smith and Gray 1990) . The present study was under taken to examine the question of whether orexigenic and anxiolytic-like effects of NPY can be anatomically dissociated, and to test the hypothesis that anxiolytic like effects of NPY are produced in the amygdaloid com plex. An established animal model of anxiety, the Geller-Seifter punished responding test (Pollard and Howard 1979 ) was used to assess anticonflict/anxiolytic like effects. Food intake as well as conflict behavior were studied both after ICV injection of NPY and after microinjections into the central amygdaloid nucleus. Since a heterogeneity of central NPY receptors has been demonstrated (Wahlestedt et al. 1990; Aicher et al. 1991) , selective ligands for NPY-Y1 and Y2 receptors were used to characterize the receptors involved in producing anxiolytic-like effects of NPY.
MATERIALS AND METHODS

Subjects
Male albino Wistar rats, weighing between 200 and 275 g at the start of the experiment were used. Animals were housed three per cage, in a light-and temperature controlled environment. For operant training and test ing, rats were food deprived to 85% of their free-feeding weight, and then maintained on 15 g food per day in addition to that earned during testing. The following groups of animals were used: ICV injections of NPY/ conflict testing (n = 32, also used for the tail-flick test; these data have been published as a part of another study [Heilig et a1. 1992] ); amygdala injections of NPY and analogs/conflict testing (n = 30; these animals were used in three separate experimental trials; they were allowed at least 7 treatment-free days after each of these, and were rerandomized for each trial); striatum injec tions of NPY/conflict testing (n = 15); ICV injections of NPY/food intake (n = 16); and amygdala injections of NPY/food intake (n = 16). All experimental proce dures were approved by the animal ethics committee at the San Diego VA Medical Center.
Surgical Procedure and Injections
Under halothane anesthesia, animals were stereotacti cally implanted with guide cannulas, which were se-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.4 cured to the skull using stainless-steel screws and acrylic cement, and were closed with obturators when not used. At least 10 days of recovery were allowed after surgery. For ICV experiments, 23-gauge guide cannulas aimed 1 mm dorsal to a planned injection site in the lateral cerebral ventricle were used (flnal coordinates: 0.6 mm posterior and 2.0 mm lateral to bregma, 4.2 mm ventral to skull surface; tooth bar at +5.0 mm); pep tide or vehicle was injected over 1 minute through a 3D-gauge injector connected to a Hamilton syringe in a volume of 51 . .tl. Conflict testing was started 60 minutes following injection. For amygdala injections, bilater� 26-gauge guides aimed 3.0 mm dorsal to the final injec· tion site were used (2.3 mm posterior and 4.2 mm late� to bregma, 8.1 ventral to skull surface; tooth bar at -3.3 rnrn), and injections were given over 3 minutes through a 33-gauge injector in a volume of 0.5 Ill. Conflict test· ing was performed 15 minutes after injection of drug. For intrastriatal injections, the same procedure was used as for the amygdala experiments, but the flnal coor· dinates were 1.0 mm anterior and 3.0 mm lateral to bregma, 5.0 mm ventral to skull surface; tooth bar at -3.3 rnrn. For the site injections, injectors were inserted and left in place for 3 minutes 2 days prior to the fust actual injection to minimize nonspeciflc injection ar tifacts upon subsequent injections. For ICV injections, correct placement was ensured by gravity injection of Sill saline prior to experiments. For site injections, coor· dinates were histologically verifled.
Conflict Test
Training and testing of animals was performed in sound-attenuated operant chambers (Coulbourn instru ments, Inc., Lehigh Valley, PA). Chambers were equipped with stainless-steel bar floors through which electric shock could be delivered. Animals were frrst trained to lever-press for 45 mg of Noyes food pellets on a continuous reinforcement schedule. They were subsequently switched to a random-interval 30-second reinforcement schedule, and flnally trained on I multiple-schedule conflict test with incremental shock (Pollard and Howard 1979) . The conflict test consisted of three components: a pure reward (unpunished) com ponent, a time-out component, and a conflict (pun ished) component. Responses made during the reward component were reinforced on a random-interval � second schedule in a darkened chamber. The chamber was illuminated with a house light during the time-out component, and responses were not reinforced . The third component (conflict) was signaled by three flash ing lights above the lever (l/sec) and responses were both rewarded with food and punished with footshocks on a continuous reinforcement schedule. Footshoa consisted of a scrambled biphasic square-wave pro-dIKed by a SGS-003 stimulator (BRS/L VE Division of Tedrical Services Inc., Laurel, MD). During the conflict CIIIl ponent, shock was incremental in 0.15-mA steps IDa maximum of 3.3 rnA with delivery of every rein bee r.
A testi ng session consisted of a 5-minute reward period, a 2-minute time-out, and a 2-minute conflict period presented in succession, with this sequence ipeated twice. Testing sessions were repeated on suc assi ve days, at the same time of day. For each animal, t.eline responding during both unpunished and pun ihed components of the test was determined over two "three sessions preceding the session during which drug effects were studied. For each subject, respond �during the actual testing session (number of lever pmse s) was expressed as a percentage of this individ ui's baseline.
fGocl Intake Experiments bseparate experiments, food intake was also measured in animals that had not undergone training for the aIlIfIict test. Free-feeding rats were placed one per cage, tJId habituated over 3 days to the introduction of a Ninless-steel bowl containing a preweighed amount m Noyes precision pellets identical to those used in the Clll lfti cttest. On the experimental day, sawdust was re lOVed, the bowl was introduced, and remaining food liICluding spill) was weighed after 30 minutes, 1 hour, lid 2 hours.
Tai1-Flick Test
Atai1-flick test was performed immediately following dlesession during which effects of ICV NPY on conflict flehavior had been studied. In this test, rats were held, mel the tail was dipped 3.5 cm in 55°C water. The illency for the tail to flick was measured (Jansen, 1963) .
Mtical Analysis
IotMlntake. The consumed amount of food at 30, 60, -' UO mi nutes was subjected to a two-way analysis afvariance with respect to treatment, time, and the in iaction between these two.
CltfIiet Test. The percent change of unpunished and panished responding versus pretrial baseline were npmtely subjected to one-way analysis of variance lilhrespect to treatment. Multiple comparisons versus atrols were performed using Dunnett's test.
Cllemi cals
Fwdne NPY, p[Leu 3 1,Pro34]NPY and NPY 13-36 were all alltain ed from Bachem California (Torrance, CAl.
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RESULTS
Effects of Intracerebroventricular NPY
Conflict Behavior. In the conflict experiment, average baseline responding on the unpunished component was 213.4 ± 11.2 lever presses per session, and on the punished component 19.3 ± O.Blever presses per ses sion (mean ± SEM). Neuropeptide Y (0.2 to 5.0 nmol) increased punished responding in a dose-dependent manner (F[26,3] = 9.0, P < .001). At the highest dose, punished responding was doubled (p < .001 vs. con trols). A smaller increase in unpunished responding was also seen (F[26,3] = 4.2, P < .015), but was at most about 30%, and had already reached a plateau at 1.0 nmol (Fig. 1) .
Very similar results were observed in a replication of this experiment in a separate group of rats. The doses of 0.2, 1.0 and 5.0 nmol ofNPY (Lc.v.) produced a dose dependent increase in punished responding reaching a maximum of 161 % of control, with no significant ef fect on unpunished responding. p< .001). There was no signihcant interaction between treatment and time (Fig. 2) .
Pain Threshold. In the tail-flick experiment that fol lowed administration of NPY to determine possible effects on pain threshold, no difference in latency to tail flick was seen, indicating that the increase in pun ished responding was not due to the analgesic effects ofNPY (2.5 ± 0.7, 1.7 ± 0.2, and 1.7 ± 0.1 second; mean ± SEM for NaCl, and 0.2, 1.0, and 5.0 nmol NPY, respectively; (F[26,3] = .77, P < .52, not signifIcant).
Effects of NPY and Its Analogs in the
Central Nucleus of the Amygdala Food Intake. Free-feeding animals injected with NPY (100 pmollside) in the central amygdaloid nucleus did not differ from vehicle-treated controls (F[ 42,2,2,1] = 1.1, P = .32, not signifIcant; Fig. 3 ).
Conflict Behavior After NPY Microinjection. Average baseline responding on the unpunished component was 359.6 ± 34.6 lever presses per session, and on the punished component 24.8 ± 0.8 lever presses per ses sion (mean ± SEM). NPY markedly increased punished responding both at the 50 and the 100 pmollside dose (F[25,2] = 7.7, P = .002 for overall treatment effect; both groups differed from controls at p < .01 on Dunnett's test). Both doses were equally efficacious, indicating an EDso below 50 pmollside. Unpunished responding was not affected (Fig. 4) . age baseline responding on the unpunished component was 307.3 ± 32.5, and on the punished component 22.5 ± 1.6 lever presses per session (mean ± SEM). The YI agonist produced an increase of punished responding of a magnitude similar to that seen with native NPY at both 50 and 100 pmollside (F[21,2] = 6.7, P = .m; for overall treatment effect; both groups differed from vehicle-injected controls at p < .01 on Dunnett's test) .
Also here, both doses were equally efficacious, indicat· ing an ED50 below 50 pmollside. Unpunished respond ing was not affected (Fig. 5) .
Conflict Behavior After Microinjection of the Selectiw
NPY-Y2 Agonist NPY13-3 6. Average baseline re spond· ing on the unpunished component was 319.6 ± 43.6, and on the punished component 25.75 ± 1.Blever presses per session (mean ± SEM). The Y2 agonist was markedly less potent than NPY in producing a release of punished responding, requiring a dose of 200 pmollside for a signifIcant effect (F[23,2] = 4.0, P = .033 for the overall treatment effect; the 100 pmollside group not signifIcantly different from controls, the 200 pmoV side different at p = .037 on Dunnett's test). The un punished component was not affected (Fig. 6) .
Effects of Intrastriatal Microinjection of NPY
Average baseline responding was 492.9 ± 30.7 on the unpunished, and 17.9 ± 1.5 on the punished compo- IS the site specifIcity of the effects produced by mi aoinjections into the central nucleus of the amygdala.
DISCUSSION
lathe present study, ICV administration of NPY pro daced both a robust increase in food intake, and a riease of punished responding in the Geller-Seitter Clll lfti ct test. The latter effect is similar to that seen with Jll*XYP icai anxiolytics, and is therefore termed "anxio- tary tract. In a vast majority (80%) of these afferents, NPY is colocalized with norepinephrine (Zardetto Gray 1990, Riche et al. 1990 ).
In the present study, doses of NPY as low as 50 pmol/side injected into the amygdala produced a max imal anxiolytic-like effect in the conflict test. No effects on the nonspecmc, unpunished component of the test were seen. In a separate experiment, a higher NPY dose (100 pmol/side) did not increase food intake in free feeding rats after microinjection into the central nucleus. These observations are in agreement with studies by others. It has previously been shown that doses in this range increase food intake after injection into the hypothalamic paraventricular nucleus (Stanley and Leibovitz 1985) , but are without effect on this parame ter after administration into the amygdala . The results of the present study support the hypothesis that the anxiolytic-like action of NPY is in dependent of the peptide's orexigenic effects, that the two effects are mediated by different anatomic struc tures, and that the central amygdaloid nucleus, at least in part, mediates the anxiolytic-like effects of NPY.
A heterogeneity of NPY receptors was initially pro posed in the peripheral nervous system. It was sug gested that one receptor population, termed Y1, re-quired the full amino acid sequence of NPY for activation, although Y2 receptors could also be activated by shorter, C-terminal fragments of NPY, such as NPY13-36 (Wahlestedt et al. 1986) . Evidence fromfunc· tional studies as well as binding experiments (Heilig et al. 1988; Wahlestedt et al. 1990; Aicher et al. 1991) confrrmed that a similar heterogeneity of NPY recep tors was also present in the brain. In a previous study, ICV administration of NPY produced anxiolyti c-like effects, and NPY13-36 was ineffective. Based on this negative evidence, it was hypothesized that anxiolytic like actions of NPY are likely to be mediated by Y1 recep tors (Heilig et al. 1989) . Recently, a selective Y1 agonist, p[Leu 31 ,Pro 3 4]NPY became available (Fuhlendorff et al. 1990 ). In the present study, the Y1 agonist was approx imately equipotent with native NPY in producing are lease of punished responding, and NPY 13-36 was markedly less potent. Such a hierarchy of potencies is characteristic of the recently cloned Y1 receptor (Larhammar et al. 1992 ). These results therefore repre sent the frrst positive evidence that the anxiolytic-like action of NPY is mediated by Y1 receptors. In periph eral sympathetic neuroeffector junctions, NPY coexists with norepinephrine, and potentiates postsynapticac tions of the latter transmitter by activating Y1 recep tors (Wahlestedt et al. 1990 ). Since a similar colo caliza. tion seems to be present in the central amygdaloid nucleus (Zardetto-Smith and Gray 1990; Riche et al. 1990 ), NPY could exert its anxiolytic-like effect on this structure in an analogous manner. However, NPYin the amygdala also coexists with somatostatin and gamma-aminobutyric acid in a population of intrinsic interneurons similar to those seen in the neocortex and striatum (McDonald 1989; McDonald and Pearson 1989) . It remains to be established whether brain-stem afferents, local interneurons, or both are involved in mediating the anxiolytic-like effects of NPY.
It has been reported that the concentration of NPY like immunoreactivity is decreased in the cerebrospi nal fluid of depressed patients (Wider16v et al. 1988) and in brain tissue of suicide victims (Widdowson eI al. 1992) , suggesting that NPY could be involved in the pathogenesis of the depressive syndrome, or parts thereof. Interestingly, in the depressed patient popu lation, a negative correlation between NPY-like im munoreactivity and anxiety scores was observed. Fur· thermore, high-performance liquid chromatography analysis of the immunoreactive material revealed that only a single peak, coeluting with native NPY was pres ent in the controls, whereas peaks representing im munoreactive material of smaller molecular size were also detected in the patients (Heilig and Widerlov 1m).
The results of the present study suggest that activation of Y1 receptors is required to produce antianxiety effects of NPY. Such an activation would require the full se quence of NPY. An increased processing and/or me-Ildism of NPY to shorter fragments could therefore mate an important endogenous antianxiety signal, III thus might contribute to anxiety symptoms seen I depression.
